The Pharmaceutical Journal
Vol 273 No 7330 p878
18/25 December 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Novartis corrects misleading Clozaril statement

Novartis Pharmaceuticals has issued a corrective statement at the request of the Medicines and Healthcare products Regulatory Agency following the voluntary withdrawal earlier this year of two promotional booklets for Clozaril (clozapine). Novartis has accepted that the overall message of the booklets — that replacing Clozaril with generic clozapine would increase treatment costs and place patients at risk — was misleading. The company accepts that there was insufficient evidence to support the claims.